JP7482487B2 - 鎮静薬を含む徐放性医薬組成物およびその使用 - Google Patents

鎮静薬を含む徐放性医薬組成物およびその使用 Download PDF

Info

Publication number
JP7482487B2
JP7482487B2 JP2021513789A JP2021513789A JP7482487B2 JP 7482487 B2 JP7482487 B2 JP 7482487B2 JP 2021513789 A JP2021513789 A JP 2021513789A JP 2021513789 A JP2021513789 A JP 2021513789A JP 7482487 B2 JP7482487 B2 JP 7482487B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
lipid
dexmedetomidine
anesthetic
liposome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021513789A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022500398A (ja
JP2022500398A5 (cg-RX-API-DMAC7.html
Inventor
ホン,キールン
グワスニー,ウォルター
カオ,ハオ-ウェン
リン,イ-ユ
Original Assignee
タイワン リポソーム カンパニー リミテッド
ティーエルシー バイオファーマシューティカルズ、インク.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by タイワン リポソーム カンパニー リミテッド, ティーエルシー バイオファーマシューティカルズ、インク. filed Critical タイワン リポソーム カンパニー リミテッド
Publication of JP2022500398A publication Critical patent/JP2022500398A/ja
Publication of JP2022500398A5 publication Critical patent/JP2022500398A5/ja
Application granted granted Critical
Publication of JP7482487B2 publication Critical patent/JP7482487B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021513789A 2018-09-13 2019-09-12 鎮静薬を含む徐放性医薬組成物およびその使用 Active JP7482487B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862730713P 2018-09-13 2018-09-13
US62/730,713 2018-09-13
PCT/US2019/050767 WO2020056102A1 (en) 2018-09-13 2019-09-12 Sustained-release pharmaceutical compositions comprising of a sedative drug and uses thereof

Publications (3)

Publication Number Publication Date
JP2022500398A JP2022500398A (ja) 2022-01-04
JP2022500398A5 JP2022500398A5 (cg-RX-API-DMAC7.html) 2022-09-09
JP7482487B2 true JP7482487B2 (ja) 2024-05-14

Family

ID=69777824

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021513789A Active JP7482487B2 (ja) 2018-09-13 2019-09-12 鎮静薬を含む徐放性医薬組成物およびその使用

Country Status (6)

Country Link
US (1) US12629354B2 (cg-RX-API-DMAC7.html)
EP (1) EP3849532A4 (cg-RX-API-DMAC7.html)
JP (1) JP7482487B2 (cg-RX-API-DMAC7.html)
CN (1) CN112654348A (cg-RX-API-DMAC7.html)
TW (1) TWI755629B (cg-RX-API-DMAC7.html)
WO (1) WO2020056102A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12472158B2 (en) * 2019-02-27 2025-11-18 Vanderbilt University Methods of treating trigeminal nerve pain
WO2021211575A1 (en) * 2020-04-13 2021-10-21 The Regents Of The Univefisity Of California Compositions comprising propofol, ketamine, and non-opioid analgesic, and methods of use
CN116688137B (zh) * 2023-07-21 2024-05-14 中国医学科学院北京协和医院 一种基于核壳结构的药物组合物及应用
CN118986892A (zh) * 2024-09-29 2024-11-22 济南大学 一种醋酸阿比特龙胆盐脂质体组合物及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012091054A1 (ja) 2010-12-27 2012-07-05 テルモ株式会社 リポソーム組成物およびその製造方法
JP2016513655A (ja) 2013-03-13 2016-05-16 マリンクロッド エルエルシー 修飾されたドセタキセルリポソーム製剤
JP2016518340A (ja) 2013-03-15 2016-06-23 タイワン リポソーム カンパニー リミテッド 水性及び非水性区画の両方におけるリポソーム組成物による制御薬物放出プロファイルの操作
WO2017062875A1 (en) 2015-10-08 2017-04-13 The Children's Medical Center Corporation Compositions and methods for on-demand high-efficiency triggerable anesthesia
WO2017123588A1 (en) 2016-01-11 2017-07-20 Merrimack Pharmaceuticals, Inc. Inhibiting ataxia telangiectasia and rad3-related protein (atr)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5942241A (en) 1995-06-09 1999-08-24 Euro-Celtique, S.A. Formulations and methods for providing prolonged local anesthesia
IL140892A0 (en) 1998-08-12 2002-02-10 Yissum Res Dev Co Liposomal bupivacaine compositions prepared using an ammonium sulfate gradient
AU2003298738A1 (en) 2002-11-26 2004-06-18 Su-Ming Chiang Liposomal formulations
AU2005281352B2 (en) * 2004-09-09 2011-01-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal compositions of glucocorticoid and glucocorticoid derivatives
CN101756902B (zh) * 2008-12-23 2011-10-05 上海医药工业研究院 一种可乐定多囊脂质体及其制备方法
US20130096170A1 (en) * 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
CA2872519C (en) 2012-05-04 2017-09-05 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
KR102310786B1 (ko) 2013-02-01 2021-10-12 존원 파마, 인코포레이티드 리포좀 내로 난수용성 약물의 원격 부하
WO2016141167A1 (en) * 2015-03-03 2016-09-09 Cureport, Inc. Combination liposomal pharmaceutical formulations
US9931298B2 (en) 2015-05-26 2018-04-03 Comfort Care For Animals Llc Liposome loading
EP3829539A4 (en) 2018-08-02 2022-05-04 Taiwan Liposome Company, Ltd. DELAYED RELEASE COMPOSITIONS WITH A THERAPEUTIC AGENT FOR THE TREATMENT OF DEPRESSION OR ANXIETY AND USES THEREOF
WO2020033195A1 (en) 2018-08-08 2020-02-13 Taiwan Liposome Co., Ltd. Sustained-release pharmaceutical compositions comprising an antipsychotic drug and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012091054A1 (ja) 2010-12-27 2012-07-05 テルモ株式会社 リポソーム組成物およびその製造方法
JP2016513655A (ja) 2013-03-13 2016-05-16 マリンクロッド エルエルシー 修飾されたドセタキセルリポソーム製剤
JP2016518340A (ja) 2013-03-15 2016-06-23 タイワン リポソーム カンパニー リミテッド 水性及び非水性区画の両方におけるリポソーム組成物による制御薬物放出プロファイルの操作
WO2017062875A1 (en) 2015-10-08 2017-04-13 The Children's Medical Center Corporation Compositions and methods for on-demand high-efficiency triggerable anesthesia
WO2017123588A1 (en) 2016-01-11 2017-07-20 Merrimack Pharmaceuticals, Inc. Inhibiting ataxia telangiectasia and rad3-related protein (atr)

Also Published As

Publication number Publication date
WO2020056102A1 (en) 2020-03-19
CN112654348A (zh) 2021-04-13
EP3849532A4 (en) 2022-06-08
EP3849532A1 (en) 2021-07-21
JP2022500398A (ja) 2022-01-04
TW202023618A (zh) 2020-07-01
TWI755629B (zh) 2022-02-21
US12629354B2 (en) 2026-05-19
US20220054455A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
US12629354B2 (en) Sustained-release pharmaceutical compositions comprising of a sedative drug and uses thereof
US12268781B2 (en) Sustained-release pharmaceutical compositions comprising a therapeutic agent for treating dementia and uses thereof
US12005142B2 (en) Sustained-release compositions comprising a therapeutic agent for treating depression or anxiety and uses thereof
EP3849523A1 (en) Sustained-release ophthalmic pharmaceutical compositions and uses thereof
JP2022500398A5 (cg-RX-API-DMAC7.html)
US12285524B2 (en) Sustained-release pharmaceutical compositions comprising an antipsychotic drug and uses thereof
JP7477844B2 (ja) 免疫調節剤を含む徐放性医薬組成物およびその使用
HK40046574A (en) Sustained-release pharmaceutical compositions comprising of a sedative drug and uses thereof
TWI729562B (zh) 包含用於治療因骨密度降低或軟骨損失導致之疾病的治療劑的緩釋藥物組合物及其用途
HK40043627A (en) Sustained-release pharmaceutical compositions comprising a therapeutic agent for treating dementia and uses thereof
HK40054350A (zh) 含有免疫調節劑的緩釋藥物組合物及其用途
HK40045697A (en) Sustained-release compositions comprising a therapeutic agent for treating depression or anxiety and uses thereof
HK40046579B (en) Sustained-release pharmaceutical compositions comprising an antipsychotic drug and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220901

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220901

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230810

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231003

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240401

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240416

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240401

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240419

R150 Certificate of patent or registration of utility model

Ref document number: 7482487

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150